Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selevtivity for MCT4 over MCT1.

Abstract: A rail transport system having no internal drive is used for conveying bulk materials and includes an over-under bypass arrangement. The bypass arrangement includes drives, ramps and switches that allow trains to travel in both directions on two sets of tracks positioned above the same track footprint. Rail bypass arrangements for use with rail transport systems for conveying bulk materials and allowing bypass of a first train and a second train are also disclosed herein.

Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

Abstract: A current monitor for a transmission line having powered active components is provided. A current monitor includes: a housing configured to be coupled to a transmission line, an inductive current sensor in the housing configured to measure a value of the current on the transmission line to generate a sensor signal, a power source, and a sensor signal conversion circuit in the housing configured to receive power from the power source and to generate a current output signal based on the sensor signal, the current output signal having a natively useful form.

Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of RhoGTPases for the treatment or prevention of cancer.

Abstract: A computer implemented method of identifying one or more relationships between columns in a database by determining a subset of a set of all columns of all tables in the database, the columns in the subset satisfying predetermined primary key characteristics, each predetermined characteristic being defined by a rule for identifying a column as a potential primary key; identifying one or more relationships between columns in the subset and columns in the set of all columns based on each of: primary key and foreign key relationships between columns; and relationships between columns indicated in one or more scripts, each script including instructions for accessing the database.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: Provided are certain polymorphic forms of vamorolone as well as pharmaceutical compositions and methods for their use.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: An insulator leakage current detector, an insulator leakage current detecting system, and a method of monitoring insulator leakage current using the same are provided. An insulator leakage current detector mountable on an insulator string includes a sensor to sense leakage current information of the insulator string; and a device to send a signal including the leakage current information sensed by the sensor.

Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Abstract: Disclosed herein are new heterocyclic compounds and compositions having structural Formula (I) and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.